2 Result: Arcellx
Arcellx's IND Clinical Hold and Rhythm Pharma's Breakthrough: Weight Loss in HyOb Patients
June 20th, 2023
Arcellx, Inc. (Nasdaq: ACLX) said that its CART-ddBCMA investigational new drug (IND) for the treatment of relapsed or refractory multiple myeloma (rrMM) has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The cl. Read more
Initiated with a Buy: Arcellx, Pliant Therapeutics, Tarsus Pharmaceuticals, Varonis Systems
May 18th, 2023
Several companies have recently received initiations with Buy ratings from prominent financial institutions, indicating positive outlooks for their future performance. Arcellx, Inc. (Nasdaq: ACLX) has been initiated with a Buy rating and a price t. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Member Login